A recent TikTok video features a man wearing a black baseball cap, accompanied by captions that claim “strange effects of Reta” and “ruining relationships.” He is discussing retatrutide, a novel weight-loss medication currently undergoing clinical trials. Despite its experimental status, there is considerable interest, leading some individuals to obtain the drug illegally online before it receives official approval. The TikTok user mentions a peculiar theory circulating that suggests the drug may cause individuals to “fall out of love.”
The comments section of the video is filled with personal anecdotes from users reporting what they describe as emotional numbness. One commenter notes that the drug has eliminated both food cravings and romantic desires, while another shares their experience of severe anhedonia, which is the inability to feel pleasure. A third individual mentions feeling indifferent to the majority of their surroundings, attributing this to retatrutide.
This video is part of a growing trend of viral content questioning whether certain peptides can inhibit feelings of love. While such claims may seem far-fetched, researchers are beginning to explore the possibility that these medications act as a “general reward dampener.” Targeting the brain’s reward system, specifically the mesolimbic pathway, these drugs may not only diminish appetite but inadvertently diminish joy in other aspects of life.
Retatrutide is the latest in a line of medications reported to cause “emotional flatness,” a phenomenon also noted among users of approved GLP-1 drugs, like Mounjaro. A recent case study indicates that these medications might affect areas of the brain involved in emotional processing, possibly leading to or exacerbating severe depressive symptoms.
Paul Kenny, an academic neuroscientist at the Icahn School of Medicine at Mount Sinai in New York, remarked that the widespread use of GLP-1 drugs presents a “huge experiment.” As millions of individuals begin to use these medications, researchers are only starting to gather data on their impacts on both behavior and physical health. Some preliminary findings have suggested unexpected connections, indicating that these drugs might influence more than just appetite and weight management. Kenny emphasized that there is still much to learn about the role of GLP-1 in the brain, although emerging research hints at potential protective benefits against neurodegenerative diseases. Recent clinical trials involving patients in the early stages of dementia have suggested that enhancing GLP-1 signaling could offer neuroprotective advantages.
Regarding the possibility that these drugs might alter emotions or social connections, Kenny expressed caution, stating he could not comment directly from a neurobiological standpoint. However, he acknowledged that it would not be surprising if medications closely linked to the body’s energy regulation also influenced human emotions and social dynamics. He noted that energy availability often impacts animal behavior, leading to changes in social interactions, such as increased territoriality when food is scarce. “GLP-1 is connected to how the brain processes rewards and pleasurable experiences,” he added.
Dr. Naveed Asif, a general practitioner at London General Practice, explained that GLP-1 medications can impact libido by affecting smooth muscle activity, which in turn can alter arousal and orgasm due to variations in blood flow to the genital area. He indicated that the chemical effects of these medications may differ among patient populations, but there is also a dopaminergic aspect at play: the hormone dopamine, which is released in response to stimuli, might decrease with the use of these peptides, leading to challenges in desire and sexual attraction, potentially impacting overall sexual function.
Asif further noted that estrogen, a crucial sex hormone, could be disrupted by GLP-1 drugs, resulting in emotional disturbances, particularly among women. He has observed that many female patients experience significant side effects that lead them to stop taking the medication, with some reporting worsened mental health, including increased depression and anxiety, which likely affects their sexual functioning as a secondary consequence.
Dr. Sophie Dix from the online pharmacy MedExpress added that while there is a perception linking “reduced food cravings” to an inability to fall in love, the science does not currently support such a leap. She emphasized that romantic attachment is a much more intricate neurobiological process than a single reward pathway. Clinical practice reveals a variety of user experiences; some report decreased libido, while others see improvements, and many of these changes can be attributed to a multitude of other factors. Research indicates that weight loss and enhanced metabolic health can boost confidence, self-image, and sexual self-esteem, often enhancing rather than diminishing desire.
Dix acknowledged that because GLP-1 drugs impact the brain’s reward centers, they may reduce compulsive behaviors, which could lead to anhedonia—the loss of enjoyment in various activities. However, she noted that this is not commonly observed, suggesting these drugs may stabilize rather than blunt the system. “This field of study is still in its infancy and merits further clinical investigation,” she remarked, encouraging patients to openly discuss any concerns related to emotional or sexual changes with their healthcare providers.
